Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
Foghorn Therapeutics to Participate at the Evercore ISI HealthCONx Conference | ||
By: GlobeNewswire - 22 Nov 2022 | Back to overview list |
|
CAMBRIDGE, Mass., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that Adrian Gottschalk, President and Chief Executive Officer, will participate in the Evercore ISI HealthCONx Conference which will be held virtually on November 30, 2022. With an initial focus in oncology, Foghorn’s Gene Traffic Control® Platform and resulting broad pipeline have the potential to transform the lives of people with a wide spectrum of diseases. Fireside chat date and time: Wednesday, November 30, 2022, at 2:40 p.m. ET Please find a link to the fireside chat here. A webcast of the fireside chat and presentation will be accessible under “Events & Presentations” in the Investors section of the Company’s website, www.foghorntx.com, and will remain available for up to 90 days. About Foghorn Therapeutics Contact: Ben Strain, Foghorn Therapeutics Inc. (Media and Investors) Karin Hellsvik, Foghorn Therapeutics Inc. (Media) Michael Lampe, ScientPR (Media) Hans Vitzthum, LifeSci Advisors (Investors) |
||
|
||
Copyright 2022 GlobeNewswire | Back to overview list |